IBM, Johns Hopkins unveil AI chatbot to target vaccine hesitancy To view this email as a web page,
click here No microchips here: IBM, Johns Hopkins unveil AI chatbot to tackle COVID-19 vaccine hesitancy COVID-19 tracker: J&J shot shows early success against Delta variant; Germany suggests vaccine mixing AGC Biologics expands further in Colorado with purchase of Novartis Gene Therapies plant Featured Story | By Andrea Park The chatbot, accessible via desktop and mobile devices, was designed specifically to be used by young people in U.S. communities disproportionately affected by COVID-19 who may be finding it difficult to find credible information about the vaccines. read more |
| |
|---|
|
| | Webinar: New Trends in Virtual Trials Monday, July 26 | 11am ET / 8am PT Last year, clinical trial platform developer Medable raised $91M in private funding, amid the COVID-19 pandemic that touched off huge demand among pharma companies looking to initiate “siteless” or virtual clinical trials. Explore the role of CROs in siteless trials and the opportunities and challenges for CROs to expand their capabilities in this burgeoning area. Register now. |
Top Stories By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Johnson & Johnson said its vaccine produced “strong, persistent activity” against the troublesome Delta variant, first found in India, when studied in the lab. Meanwhile, Germany is suggesting people who received the AstraZeneca shot as a first dose use an mRNA vaccine for their second shot. And more headlines. read more By Fraiser Kansteiner Angling to bolster cell and gene production, AGC Biologics has clinched a deal for a commercial Novartis Gene Therapies factory in Longmont, Colorado. Located just 16 miles from AGC’s 20,000-liter mammalian facility in Boulder, the new plant is expected to add “significant additional capacity" for the contract manufacturer. read more | | Webinar: COVID-19 Virus Sequencing for Drug Development Wednesday, July 28 | 10:30am ET / 7:30am PT As new COVID-19 variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development. This webinar will connect insights from population surveillance to potential solutions for drug developers, outline approaches to COVID-19 virus sequencing and more. Register Now. |
|
|
